The University of Colorado Cancer Center (UCCC) is the only NCI-designated comprehensive Cancer Center in Colorado serving a primary catchment area of Colorado and Wyoming with a population of ~5.5M. During the past five years, peer-reviewed cancer-related funding reached $102M and 3,181 publications (35% collaborative) were produced. Outpatient visits and clinically active faculty are growing, which will translate into a ranked increase in patient accruals to clinical trials. UCCC is an NCI-recognized consortium encompassing Univ. of Colorado Boulder, Colorado State University, National Jewish Health, Univ. of Colorado Hospital (UCH), the Colorado Children's Hospital, Denver Health System, Kaiser Permanente of Colorado and the Denver Veterans Administration Medical Center. We also have a growing number of outreach clinics staffed directly by our faculty including Montrose Hospital in Montrose, Valley View Hospital in Glenwood Springs, and Vail Valley Medical Center in Edwards. Our affiliates (CGOPs) include St. Mary's in Grand Junction. UCH has constructed a new outpatient tower for oncology care (opened May 2012), and is nearing completion of a new inpatient tower (March 2013). UCH has merged with our former affiliates, Poudre Valley Medical Center (PVMH) in Ft. Collins and Memorial Hospital (MH) in Colorado Springs, under the unified University of Colorado Health Systems. The cancer components of these two hospital systems will formally join the UCCC consortium later this year. The LAPS U10-funded membership in the NCTN and in SWOG and NRG fulfills many of the goals of our Cancer Center by providing broad access to innovative Phases II and III treatment and chemoprevention trials to the citizens of Colorado. This grant provides partial support for the monitoring and oversight to run clinical trials at the main institutions. Our faculties have provided strong administrative and scientific leadership, throughout the NCTN, by serving or chairing SWOG and RTOG committees, serving as PIs for Phases ll/lll SWOG, GOG, ACOSOG, RTOG, and NSABP group trials including PLCO, PCPT, SELECT and NLST/ACRIN. Clinical trials represent the state-of-the-art in cancer treatment and prevention and should be broadly available and offered to the citizens of Colorado.
As the only NCI-designated Cancer Center in the State of Colorado, the UCCC innovates in the development of more effective approaches to prevention, diagnosis, and therapy of cancer. Clinical trials, especially Phase III studies, drive progress and establish new standards of care (SOC). This grant provides essential resources to support these clinical trials to our Cancer Center and to multiple sites around the Rocky Mountain region. Access to clinical trials is crucial for excellence in health care.
|Fakhry, Carole; Zhang, Qiang; Nguyen-Tân, Phuc Felix et al. (2017) Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. J Clin Oncol 35:4057-4065|
|Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703|
|Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753|
|Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465|
|Winchester, Danyelle A; Till, Cathee; Goodman, Phyllis J et al. (2017) Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate 77:908-919|
|Coleman, Robert L; Brady, Mark F; Herzog, Thomas J et al. (2017) Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:779-791|
|Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637|
|Platz, Elizabeth A; Kulac, Ibrahim; Barber, John R et al. (2017) A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiol Biomarkers Prev 26:1549-1557|
|Tsodikov, Alex; Gulati, Roman; Heijnsdijk, Eveline A M et al. (2017) Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Ann Intern Med 167:449-455|
|Olsen, Jeffrey R; Moughan, Jennifer; Myerson, Robert et al. (2017) Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529. Int J Radiat Oncol Biol Phys 98:400-408|
Showing the most recent 10 out of 54 publications